BEDFORD, Mass., June 22 /PRNewswire-FirstCall/ -- Hologic, Inc. (Hologic or the Company) (Nasdaq: HOLX), a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, announced today that the Hologic Selenia® digital mammography system with a tungsten tube has received "Mammographic Type Test" certification by the European Reference Organization (EUREF) Council for Quality Assured Breast Screening and Diagnostic Services. The Hologic system is the first mammography system of any type to receive this certification.
To view the multimedia assets associated with this release, please click: http://multivu.prnewswire.com/mnr/hologic/39361/
The mission of the non-profit EUREF council is to raise standards by bringing together at the EU level the best examples of quality control in mammography screening from regional and national breast cancer screening programs. EUREF mammographic type test certification ensures hospitals and imaging centers that Hologic's Selenia systems have passed a rigorous series of physics and clinical tests demonstrating that the systems meet the image quality, radiation exposure, and stability standards set out by EUREF for screening and diagnostic mammography equipment.
"Our customers tell us they buy the Selenia system for a number of reasons. Two reasons show up on almost everyone's list - exceptional image quality and low patient dose," notes Peter Soltani, Senior Vice President of Breast Health at Hologic. "The EUREF mammographic type test confirms what we've learned through our own clinical trials and scientific investigations - the Selenia system is optimal for use in mammography. With more than 6,000 systems installed, Selenia is the most popular digital mammography system in the world."
About Hologic, Inc.
Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women. Hologic's core business units are focused on breast health, diagnostics, GYN surgical, and skeletal health. Hologic provides a comprehensive suite of technologies with products for mammography and breast biopsy, radiation treatment for early-stage breast cancer, cervical cancer screening, treatment for menorrhagia, permanent contraception, osteoporosis assessment, preterm birth risk assessment, mini C-arm for extremity imaging and molecular diagnostic products including HPV and reagents for a variety of DNA and RNA analysis applications. For more information, visit www.hologic.com.
Forward Looking Statement Disclaimer
This News Release may contain forward-looking information that involves risks and uncertainties, including statements about the use of the Selenia digital mammography system. There can be no assurance the system will achieve the benefits described herein and that such benefits will be replicated in any particular manner with respect to an individual patient as the actual effect of the use of the Selenia system can only be determined on a case-by-case basis depending on the particular circumstances and patient in question. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to the data or statements presented herein to reflect any change in the Company's expectations or any change in events, conditions or circumstances on which any such data or statements are based.
Hologic and Selenia are trademarks and/or registered trademarks of Hologic, Inc., and/or its subsidiaries in the United States and/or other countries.
SOURCE Hologic, Inc.